The efficacy of the administration of SGLT-2 inhibitor and/or DPP-4 inhibitor in type 2 diabetic patient with basal-bolus insulin therapy.

The efficacy of the administration of SGLT-2 inhibitor and/or DPP-4 inhibitor in type 2 diabetic patient with basal-bolus insulin therapy. - The effect of SGLT-2 administration on nocturnal hypoglycemia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020742

Enrollment

Registered

2016-01-27

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

ipraglifrozin 50mg teneligliptin 20mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients who are hospitalesed for glycemic control and never recieved insulin therapy

Exclusion criteria

Exclusion criteria: Type 1 diabetes renal dysfunction hepatic dysfunction

Design outcomes

Primary

Measure	Time frame
The effect of drugs on glycemic control estimated by frequent blood collection and continuous glucose monitoring system	—

Secondary

Measure	Time frame
insulin dose	—

Countries

Japan

Contacts

Public ContactFumitaka Okajima

Chiba-Hokusoh Hospital, Nippon Medical School Division of Endocrinology, Department of Medicine

okaji@nms.ac.jp0476-99-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026